Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Lymphoid 1

Conditions

Breast Neoplasms 2Ventricular Dysfunction, Left 1Lymphoma, Large B-Cell, Diffuse 1Cardiotoxicity 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Nebivolol × Clear all
NCT07233499 2025-11-19

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients

Ain Shams University

Phase 2 Recruiting
56 enrolled
Breast

Breast Neoplasms

NCT05728632 2023-02-23

CONTROL

Humanitas Hospital, Italy

Phase 3 Unknown
80 enrolled
BreastLymphoid

Breast Neoplasms, Lymphoma, Large B-Cell, Diffuse, Ventricular Dysfunction, Left, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡